Established in 2018, InxMed strives to be a China-based global new drug development engine dedicated to the development of innovative drugs with high probability of success and meaningful value for patients globally by execution of our “Best-in-Disease Combination” strategy and leveraging China clinical resources. In InxMed, we think differently, because we know the deep understanding of disease biology and value-driven study design are how we differentiate from others. In InxMed, we value the highest efficiency in execution and expeditious generation of “PoC” data, because we know “Vision without execution is hallucination”. In InxMed, we believe combination therapy is the future for oncology, and triple or multiple drug combinations are emerging with great potential. In InxMed, we strive to build up a pipeline consisting of “First-in-Class” and “Best-in-Disease Combination” assets, driven by intrinsic potential of synergy.
View Top Employees from InxMed 应世生物Website | http://www.inxmed.com |
Revenue | $5 million |
Employees | 17 (15 on RocketReach) |
Founded | 2018 |
Address | Tower 2 Huamao Office Building No. 79 Jianguo Rd Fl 30 Rm 3007, Chaoyang District, Beijing, CN |
Phone | +86 10 8588 7500 |
Industry | Biotechnology Research, Pharmaceuticals, Oncology, Healthcare, Translation Medicine, Best-in-Disease Combination, Innovative Drugs |
SIC | SIC Code 873 Companies, SIC Code 28 Companies, SIC Code 283 Companies, SIC Code 87 Companies, SIC Code 80 Companies |
NAICS | NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 541 Companies, NAICS Code 54 Companies, NAICS Code 3254 Companies |
Looking for a particular InxMed 应世生物 employee's phone or email?
The InxMed 应世生物 annual revenue was $5 million in 2024.
James McLeod is the Executive Vice President and US Chief Medical Officer of InxMed 应世生物.
15 people are employed at InxMed 应世生物.
InxMed 应世生物 is based in Chaoyang District, Beijing.
The NAICS codes for InxMed 应世生物 are [325, 32, 541, 54, 3254].
The SIC codes for InxMed 应世生物 are [873, 28, 283, 87, 80].